Bevasiranib

DB06642InvestigationalGene Therapies

Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in macular degeneration and diabetic retinopathy.Curator reviewed

Resolves to

Compound
UNIIDGN36694W4CAS959961-96-7
Targets
O15455TLR3P15692VEGFA

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bevasiranib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In